Remedent Reports Fiscal Fourth Quarter and Record Fiscal 2009 Results

DEURLE, BELGIUM and LOS ANGELES, CA, Jun 29 (MARKET
WIRE) --
Remedent, Inc. (OTCBB: REMI), an international company specializing in
the research, development, and manufacturing of oral care and cosmetic
dentistry products, reported results for the fiscal fourth quarter and
year ended March 31, 2009 (in U.S. dollars).

Net sales in the fourth quarter totaled $3.4 million, an increase of 12%
from $3.0 million in the same year-ago quarter. Net sales for the fiscal
year 2009 totaled a record $14.6 million, an increase of 96% from $7.5
million in fiscal 2008.

The increase in net sales was primarily due to the increased sales by the
company's GlamSmile Product Group. In fiscal 2009, sales of GlamSmile(TM),
the company's leading dental veneer product, increased year-over-year by
$6.7 million or 564% to $7.9 million, compared to sales of $1.2 million in
fiscal 2008.

Loss from operations in the fourth quarter was $468,000, an improvement
from a loss of $550,000 in the same year-ago quarter. Loss from operations
for fiscal 2009 was $946,000, an improvement from a loss of $3.1 million
in fiscal 2008. The narrowing of the loss from operations is attributed
to the increase in sales, as well as reorganization of the company's
production process and more in-house manufacturing that resulted in lower
costs than the previously outsourced third party manufacturing.

Net loss for the fourth quarter totaled $1.1 million or $(0.05) per share
(after minority interest and based on 20.0 million weighted average shares
outstanding), as compared to a loss of $623,000 or $(0.03) per share
(based on 17.8 million weighted average shares outstanding) in the same
year-ago quarter.

Net loss for fiscal 2009 totaled $3.0 million or $(0.15) per share (after
minority interest and based on 19.6 million weighted average shares
outstanding), as compared to a loss of $3.1 million or $(0.17) per share
(based on 17.8 million weighted average shares outstanding) in fiscal
2008. The net loss in fiscal 2009 included $4.3 million in warrants
issued to Den-Mat Holdings, partially offset by a gain of $2.8 million
from the sale of a portion of the company's over-the-counter retail
product business.

Net comprehensive loss in the fourth quarter after foreign currency
translation adjustment was $1.3 million or $(0.07) per share, compared to
a net loss of $572,000 or $(0.03) per share in the same year-ago quarter.
Net comprehensive loss in fiscal 2009 after foreign currency translation
adjustment was $3.6 million or $(0.19) per share, compared to a net loss
of $3.1 million or $(0.17) per share in fiscal 2008.

Cash and cash equivalents totaled $1.8 million at March 31, 2009, an
increase of 5% from $1.7 million at March 31, 2008.

Management Commentary

"Fiscal 2009 represented strong progress for Remedent across the board --
operationally, in product development, and in record sales for the year,"
said Guy De Vreese, CEO of Remedent. "The year was highlighted by
dramatically increased sales of our flagship GlamSmile product, which is
being adopted increasingly by dentists around the world. The year also
represented a period of restructuring and realigning our efforts through
the divesture of our OTC business, as well as advancing the development of
our revolutionary, patent-pending FirstFit(TM) system for crowns and
bridges.

"Our FirstFit development effort culminated with the recent expansion of
our distribution agreement with Den-Mat Holdings to include FirstFit. As
the world's largest producer of dental veneers, Den-Mat's complete
adoption of our GlamSmile technology in August of 2008 has solidified our
position as a world leader in the dental veneer space. Den-Mat will now
champion the market introduction of FirstFit in the United States through
their network of more than 10,000 dentists.

"We are now beginning to emerge from a pivotal stage in our development,
with a new operational structure designed to leverage the tremendous
potential of our unique veneer technology. In addition to Den-Mat in the
United States, we are also realizing increasing success in China and
Australia. Meanwhile, we are finding ways to reduce our costs, including
doing more in-house production. We believe our wide-ranging progress in
fiscal 2009 has put us on course for continued growth and market expansion
in fiscal 2010."

Teleconference Information

Remedent will host a conference call on Wednesday, July 1, 2009 at 11:00
a.m. Eastern time to discuss these results. A question and answer session
will follow management's presentation. To participate in the call, dial
the appropriate number 5-10 minutes prior to the start time, request the
Remedent conference call and provide the conference ID.

Date: Wednesday, July 1, 2009
Time: 11:00 a.m. Eastern time (8:00 a.m. Pacific time)
Dial-In Number: 1-800-894-5910
International: 1-785-424-1052
Conference ID#: 7REMEDENT

A simultaneous webcast and replay of the call will be accessible via
this link: http://viavid.net/dce.aspx?sid=0000666B.

Please call the conference telephone number 5-10 minutes prior to the
start time. An operator will register your name and organization and ask
you to wait until the call begins. If you have any difficulty connecting
with the conference call, please contact the Liolios Group at
1-949-574-3860.

A telephone replay of the call will be available from 2:00 p.m. Eastern
time on the same day until August 1, 2009:

Toll-free replay number: 1-800-695-0395
International replay number: 1-402-220-1388
(No passcode required)

About Remedent

Remedent, Inc. specializes in the research, development, manufacturing and
marketing of oral care and cosmetic dentistry products. The company serves
professional dental industry with breakthrough technology for dental
veneers, bridges and crowns that are recognized worldwide for their
technological superiority and ease-of-application. These products are
supported by a line of professional veneer whitening and teeth sensitivity
solutions. Headquartered in Belgium, Remedent distributes its products to
more than 35 countries worldwide. For more information, go to
www.remedent.com.

Statement under the Private Securities Litigation Reform Act of 1995

Statements in this press release that are "forward-looking statements" are
based on current expectations and assumptions that are subject to risks
and uncertainties. Such forward-looking statements involve known and
unknown risks, uncertainties and other unknown factors that could cause
Remedent's actual operating results to be materially different from any
historical results or from any future results expressed or implied by such
forward-looking statements. In addition to statements that explicitly
describe these risks and uncertainties, readers are urged to consider
statements that contain terms such as "believes," "belief," "expects,"
"expect," "intends," "intend," "anticipate," "anticipates," "plans,"
"plan," "projects," "project," to be uncertain and forward-looking. Actual
results could differ materially because of factors such as Remedent's
ability to achieve the synergies and value creation contemplated by the
proposed transaction. For further information regarding risks and
uncertainties associated with Remedent's business, please refer to the
risk factors described in Remedent's filings with the Securities and
Exchange Commission, including, but not limited to, its annual report on
Form 10-K and quarterly reports on Form 10-Q.

REMEDENT, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

Three months ended Year ended
March 31, March 31,
2009 2008 2009 2008
------------ ------------ ------------ ------------
Net sales $ 3,390,355 $ 3,028,362 $ 14,639,541 $ 7,482,261
Cost of sales 1,650,315 1,352,271 6,614,723 3,975,777
------------ ------------ ------------ ------------
Gross profit 1,740,040 1,676,091 8,024,818 3,506,484
Operating Expenses
Research and
development 24,273 85,293 248,652 332,958
Sales and
marketing 370,042 889,452 2,793,970 1,886,389
General and
administrative 1,639,656 1,165,842 5,312,192 4,057,007
Depreciation and
amortization 173,903 85,319 615,674 301,260
------------ ------------ ------------ ------------
TOTAL
OPERATING
EXPENSES 2,207,874 2,225,906 8,970,488 6,577,614
------------ ------------ ------------ ------------
OPERATING LOSS (467,834) (549,815) (945,670) (3,071,130)
NON-OPERATING
(EXPENSE) INCOME
Warrants issued
pursuant to
Distribution
Agreement - - (4,323,207) -
Gain on
disposition of
OTC - - 2,830,953 -
IMDS provision (300,000) - (300,000) -
Interest
expense/other
deductions (166,972) (66,366) (417,147) (138,168)
Interest
income/other
income 1,884 20,367 348,997 -
Other income - - - 121,032
------------ ------------ ------------ ------------
TOTAL OTHER
INCOME
(EXPENSES) (465,088) (45,999) (1,860,404) (17,136)
------------ ------------ ------------ ------------
LOSS FROM
CONTINUING
OPERATIONS BEFORE
INCOME TAXES AND
MINORITY INTEREST (932,922) (595,814) (2,806,074) (3,088,266)
Income tax expense (32,633) (27,247) (32,633) (27,247)
------------ ------------ ------------ ------------
NET LOSS FROM
CONTINUING
OPERATIONS BEFORE
MINORITY INTEREST (965,555) (623,061) (2,838,707) (3,115,513)

MINORITY INTEREST (114,208) - (114,208) -
------------ ------------ ------------ ------------
NET LOSS FROM
CONTINUING
OPERATIONS $ (1,079,763) $ (623,061) $ (2,952,915) $ (3,115,513)
============ ============ ============ ============
LOSS PER SHARE
Basic and fully
diluted $ (0.05) $ (0.03) $ (0.15) $ (0.17)
============ ============ ============ ============
WEIGHTED AVERAGE
SHARES OUTSTANDING
Basic and fully
diluted 19,995,969 17,823,012 19,559,653 17,823,012
============ ============ ============ ============

OTHER COMPREHENSIVE
INCOME (LOSS):
Foreign currency
translation
adjustment (259,045) 50,608 (668,245) 60,953
------------ ------------ ------------ ------------
Comprehensive
income (loss) $ (1,338,808) $ (572,453) $ (3,621,160) $ (3,054,560)
============ ============ ============ ============
Comprehensive loss
per share $ (0.07) $ (0.03) $ (0.19) $ (0.17)
============ ============ ============ ============

REMEDENT, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

March 31, 2009 March 31, 2008
-------------- --------------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 1,807,271 $ 1,728,281
Accounts receivable, net of allowance
for doubtful accounts of $33,966 at
March 31, 2009 and $32,181 at March 31,
2008 3,208,120 1,902,920
Inventories, net 1,937,946 1,360,709
Prepaid expense 1,310,900 970,173
-------------- --------------
Total current assets 8,264,237 5,962,083
-------------- --------------
PROPERTY AND EQUIPMENT, NET 1,024,999 692,609
OTHER ASSETS
Long term investments and advances 750,000 675,000
Patents, net 163,106 115,827
-------------- --------------
Total assets $ 10,202,342 $ 7,445,519
============== ==============
LIABILITIES AND STOCKHOLDERS' EQUITY
(DEFICIT)
CURRENT LIABILITIES:
Current portion, long term debt $ 78,798 $ 58,583
Line of Credit 660,200 779,718
Accounts payable 1,398,420 2,002,439
Accrued liabilities 1,590,360 781,737
Income taxes payable 39,339 15,121
-------------- --------------
Total current liabilities 3,767,117 3,637,598
Long term debt less current portion 100,542 94,754
Minority interest 896,705 --
Total liabilities 4,764,364 3,732,352
-------------- --------------
STOCKHOLDERS' EQUITY:
Preferred Stock $0.001 par value
(10,000,000 shares authorized, none
issued and outstanding) -- --
Common stock, $0.001 par value;
(50,000,000 shares authorized,
19,995,969 shares issued and
outstanding at March 31, 2009 and
18,637,803 shares issued and
outstanding at March 31, 2008) 19,996 18,638
Treasury stock, at cost; 723,000 and 0
shares at March 31, 2009 and March 31,
2008 respectively (831,450) --
--------------
Additional paid-in capital 24,106,055 17,929,992
Accumulated deficit (17,216,028) (14,263,113)
Accumulated other comprehensive income
(loss) (foreign currency translation
adjustment) (640,595) 27,650
-------------- --------------
Total stockholders' equity 5,437,978 3,713,167
-------------- --------------
Total liabilities and stockholders'
equity $ 10,202,342 $ 7,445,519
============== ==============

Company Contacts:
Stephen Ross
Chief Financial Officer
Remedent, Inc.
Tel 310-922-5685
Email Contact

Investor Relations:
Ron Both
Scott Liolios
Managing Director
Liolios Group, Inc.
Tel (949) 574-3860
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-